Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-23-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Parvin Yenki und 17 weiteren Autor:innen. Beteiligte Einrichtung: The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Semaphorins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that is highly expressed in castration-resistant prostate cancer, can promote steroidogenesis by altering the expression profile of key steroidogenic enzymes. Semaphorin 3C not only upregulates enzymes required for androgen synthesis from dehydroepiandrosterone or de novo from cholesterol but also simultaneously downregulates enzymes involved in the androgen inactivation pathway. These changes in gene expression correlate with increased production of androgens induced by semaphorin 3C in prostate cancer model cells. Moreover, semaphorin 3C upregulates androgen synthesis in LNCaP cell-derived xenograft tumors, likely contributing to the enhanced in vivo tumor growth rate post castration. Furthermore, semaphorin 3C activates sterol regulatory element-binding protein, a transcription factor that upregulates enzymes involved in the synthesis of cholesterol, a sole precursor for de novo steroidogenesis. The ability of semaphorin 3C to promote intratumoral androgen synthesis may be a key mechanism contributing to the reactivation of the androgen receptor pathway in castration-resistant prostate cancer, conferring continued growth under androgen deprivation therapy. These findings identify semaphorin 3C as a potential therapeutic target for suppressing intratumoral steroidogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada.
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Parvin Yenki, Satyam Bhasin, Christopher J Ong
Förderung
- NCI NIH HHS
Zitieren
APA
Yenki, P., Bhasin, S., Liu, L., Nabavi, N., Cheng, C. W., Tam, K. J., Peacock, J. W., Adomat, H. H., Tombe, T., Fazli, L., Ivanova, L., Dusek, C., Khosravi, S., Guns, E. S. T., Wang, Y., Buttyan, R., Gleave, M. E., & Ong, C. J. (2023). Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0010
Vancouver
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, et al. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. Endocrine-Related Cancer. 2023. doi:10.1530/erc-23-0010
BibTeX
@article{Yenki2023,
author = {Yenki, Parvin and Bhasin, Satyam and Liu, Liang and Nabavi, Noushin and Cheng, Chi Wing and Tam, Kevin J and Peacock, James W and Adomat, Hans H and Tombe, Tabitha and Fazli, Ladan and Ivanova, Larissa and Dusek, Christopher and Khosravi, Shahram and Guns, Emma S Tomlinson and Wang, Yuzhuo and Buttyan, Ralph and Gleave, Martin E and Ong, Christopher J},
title = {Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-23-0010}
}
EUVIMED